HER2-POSITIVE GASTRIC ADENOCARCINOMA
Clinical trials for HER2-POSITIVE GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: phase 3 trial tests rilvegostomig combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…
Matched conditions: HER2-POSITIVE GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…
Matched conditions: HER2-POSITIVE GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to tackle tough stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental antibody (HLX22) to standard treatment (trastuzumab plus chemotherapy) works better for people with advanced HER2-positive stomach or gastroesophageal junction cancer. About 550 participants will be randomly assigned to rece…
Matched conditions: HER2-POSITIVE GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC